

2021 #14

April 23, 2021

INSIDE:

Paper Published on Public Policy Impact of Pandemic on U.S. Blood Supply2
 RESEARCH IN BRIEF3
 WORD IN WASHINGTON4
 ABC Highlights Need for Diverse Blood Supply in USA TODAY.....5
 Participate in the ABC Employee and Retention Survey5
 ABC Seeks Member Participation in 2020 Service Fee Survey5
 ADRP Master Class Designed for Your Collections and Recruitment Teams5
 PEOPLE6
 COVID-19 Convalescent Plasma Updates7
 GLOBAL NEWS7
 COMPANY NEWS8
 CALENDAR.....9
 POSITIONS.....10

John Miller Becomes ABC President & New ABC Board Officers Announced

John Miller, MBA has been elected as the president of the America's Blood Centers (ABC) Board of Director for fiscal years 2022 and 2023. He succeeds Mississippi Valley Regional Blood Center's Mike Parejko who will now assume the role of Past President. Mr. Miller is the president and chief executive officer of LIFELINE Blood Services in Jackson, Tenn. and has served as a member of the ABC Board since 2019.



“It is an honor to be asked to serve in this capacity,” said Mr. Miller to the *ABC Newsletter*. [This association] has been a staple in my education and understanding of our industry throughout my career. I have consistently turned to ABC to better understand what is changing and how our industry is evolving. Due to ABC's boisterous presence on Capitol Hill, our government better understands the needs of community blood centers and how they [as elected officials] can better help our industry. It is a privilege to be a part of such an important mission.”

He began his career in blood banking by accepting a summer job delivering blood throughout the eastern part of Texas — something that has turned into a now 27-year career. During this time, Mr. Miller has served in several roles at multiple blood centers within the ABC membership including Carter BloodCare and Vitalant.

As ABC President, Mr. Miller hopes that “we can continue to communicate our needs to regulators and legislators and provide all community blood centers the opportunities to grow and prosper while performing our lifesaving missions...We have a more influential and stronger presence when we speak with a united voice.”

Mr. Miller holds a Master of Business Administration degree and served on the board of directors of IT Synergistics (ITSY), and the Tennessee Association of Blood Banks (TABB).

The new slate of officers for the ABC Board of Directors has also been approved and includes:

- Vitalant's Rob Van Tuyle (Vice President)
- Carter BloodCare's Laurie Sutor, MD, MBA (Secretary/Treasurer).

(continued on page 2)

John Miller Becomes ABC President (continued from page 1)

The other members of the ABC Board of Directors are:

- Rock River Valley Blood Center's Lisa Entriokin;
- OneBlood's Martin Grable;
- LifeSouth's Kim Kinsell, JD; and
- New York Blood Center's Rob Purvis. 💧

Paper Published on Public Policy Impact of Pandemic on U.S. Blood Supply

Authors in the *American Journal of Public Health* recently published a [paper](#) that delves into the impact of the ongoing COVID-19 pandemic on the U.S. blood supply. They describe the challenges faced by blood collection organizations to maintain the availability of the nation's blood supply as stay at home orders were issued throughout the U.S., the implementation of social distancing guidelines, remote work and learning in addition to the cancellation of school and corporate blood drives. It also highlights the decrease in demand for blood from hospitals as elective procedures were cancelled and the efforts by the U.S. government to assist blood centers in raising awareness amongst eligible donors. The authors also highlight how the blood community pivoted their operations to collect COVID-19 convalescent plasma from individuals who had been diagnosed with COVID-19 and since recovered. They stress that officials need to prioritize and include the need for blood in preparedness efforts, "Blood and blood products are a critical element of public health emergency preparedness and an essential component of the Emergency Support Functions of the National Response Framework... While Congress identified ensuring an adequate blood supply as an important strategic issue facing the U.S blood system, this concern has not received sufficient attention, and there has not been substantial progress toward this goal. Although blood collection centers are among the few organizations allowed to stay open during closures of nonessential business during the pandemic, they have operated at a substantially reduced capacity, experiencing difficulty in reliably meeting blood requirements. Indeed, COVID-19 has significantly decreased the rate of blood donations around the world. Emergency preparedness for transfusion medicine is based on the assumption that demand will increase dramatically... The COVID-19 pandemic has led to a serious shortage of blood in the United States, jeopardizing the ability of the health care system to treat patients, creating a public health emergency for the foreseeable future." The paper includes 10 recommendations:

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2021 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

memberservices@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.

Public Policy Impact of Pandemic on Blood Supply Paper (continued from page 2)

- “create national policies for capacity building;
- establish national system for inventory management;
- change operating structure of blood supply organizations to improve ability to react to emergencies;
- make structural changes to improve supply chain;
- integrate blood supply organizations into emergency planning activities;
- include blood-related scenarios in emergency drill and exercise programs;
- ensure that blood suppliers have appropriate priority within emergency communications, transportation, and restoration of utilities;
- define structure for comprehensive unified crisis management related to blood supply;
- ensure that blood centers are considered essential services during emergencies; and
- create national stockpile of key supplies, equipment, and reagents to support continued blood supply organization function during emergency.”

The authors conclude that “The COVID-19 pandemic introduces severe stressors into the supply chain, contributing to the public health emergency and threatening population health. However, this acute blood shortage reflects deeper issues for public health emergency preparedness as well as the structure of the blood collection system. There is no known end date for the COVID-19 pandemic and no guarantee that COVID-19 will be the last epidemic or pandemic, underscoring the challenge to immediately identify strategies to improve long-term sustainability of the United States’ blood supply. The short-term and long-term recommendations presented in this article can be used as a call to action to help ensure an adequate and safe blood supply.”

Citation: Riley, W.; Love, K., and McCullough, J. [Public Policy Impact of the COVID-19 Pandemic on Blood Supply in the United States](#). *American Journal of Public Health*. 2021.

RESEARCH IN BRIEF

HIV Prevalence and Incidence — International Comparison of Blood Donors vs. General Population.

An article published in *Vox Sanguinis* “compare[d] the prevalence and incidence rates of HIV in blood donors and in the general population...Fourteen blood cent[er] members participated” and “obtained data on all whole blood donations over a 10-year period (2007–2016).” The study participants “carried out HIV antibody testing and HIV [nucleic acid testing] (NAT) on all donations, except for Norway, where [only] HIV NAT was performed.” The authors note, that “[f]or each country, the prevalence and incidence rates of HIV in the general population were calculated by averaging yearly statistics obtained from Global Health Data Exchange...All jurisdictions had a permanent or a temporary deferral for [men who have sex with other men] (MSM), except for Italy and Basque Country, where MSM donors were evaluated for risk [behaviors]...When comparing prevalence rates of HIV in first-time donations between regions/countries, the highest rate was observed in Sao Paolo at 65.3/105, [and was] significantly higher compared with all other jurisdictions.” The authors found that “[t]here was a “lack of correlation between the prevalence of HIV-positive donations among repeat donors and HIV incidence in the general population...Some regions or countries with very similar donor deferral policies have seemingly but non-significantly different rates of NAT-only-positive donations.” The researchers added that, “[b]ased on the incidence derived from NAT-only-positive donations and assuming a period of nine days for the [window period], the residual risk of transmission is in the order of 1 [out of] 3,125,000 donations...We also calculated the proportion of all HIV-positive donations that are NAT-only positive, as an indicator of the proportion of very recent infections, however, the observed differences [among countries] are not statistically significant...In this

(continued on page 4)

RESEARCH IN BRIEF (continued from page 3)

international comparison of the rates of HIV among donors [the study] shows that most countries have very low rates of HIV infections in their donor population and that these rates are quite comparable.” The authors state that “[t]hey are also systematically lower and, with regard to prevalence rates, associated with the rates observed in the general population...Countries that allow MSM to donate have higher rates of prevalent and incident HIV in their donor population, but the risk to recipients remains very small and is often comparable to the risk observed in some other countries with more stringent policies.”

Citation: Germain, M., Gregorie, Y., Custer, B., *et al.* [An international comparison of HIV prevalence and incidence in blood donors and general population: a BEST Collaborative study](#). *Vox Sanguinis*. 2021.

Contributed by Richard Gammon, MD, Medical Director at OneBlood ♦

WORD IN WASHINGTON

America’s Blood Centers (ABC) signed on to a Constituency Group letter on April 16th to members of Congress in support of funding for the National Institutes of Health’s (NIH) National, Heart, Lung & Blood Institute (NHLBI). The letter cosigned by 58 other organizations is addressed to Sen. Patty Murray (D-Wash.) Chair of the Senate Appropriations Subcommittee on Labor, Health and Human Services (HHS), Education and Related Agencies, Sen. Roy Blunt (R-M.O.) Ranking Member of the subcommittee, Rep. Rosa DeLauro (D-Conn.) Chair of the House Appropriations Subcommittee on Labor, HHS, Education and Related Agencies, and Rep. Tom Cole (R-O.K.) Ranking Member of the subcommittee. It urges the members of Congress to “include in the FY 2022 Labor-HHS-Education Appropriation bill \$46.11 billion for the NIH, including \$3.94 billion for NHLBI. A funding level of this amount would allow the NIH to address critical needs related to the ongoing COVID-19 pandemic, including health disparities and long haul COVID syndrome, sustain current activities and invest in promising and critically needed scientific research. An FY 2022 appropriation of \$46.11 billion for the NIH, including \$3.94 billion for NHLBI would permit the NIH to capitalize on its ability to enhance patient health and care, boost economic growth, and promote scientific discovery.” The letter adds that, “To continue important advances in research, the NHLBI is investing in prevention programs and new treatments for cardiovascular disease including congenital heart disease, developing novel therapies for lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, cystic and pulmonary fibrosis, improving the treatment of blood disorders such as sickle cell disease and hemophilia, and driving precision medicine that is tailored to individual patient needs through data science. As the worldwide leader in research on heart, lung, blood, and blood vessel diseases as well as sleep disorders, the NHLBI effectively translates research results to the American public.” The full letter is [available](#) on the ABC public website.

(Source: NHLBI Constituency Group [Letter](#), 4/16/21)

U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra, JD announced that the public health emergency for COVID-19 has been extended for another 90 days. The declaration was scheduled to expire this month and this extension will continue the public health emergency into July 2021. The declaration allows the Administration to provide response aid to local state health departments in addition to flexibility for government-run health insurance programs and emergency approvals of new drugs and tests.

(Source: HHS [Announcement](#), 4/15/21) ♦





America's Blood Centers
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

ABC Highlights Need for Diverse Blood Supply in USA TODAY

America's Blood Centers participated in a campaign with *USA Today*, by authoring an [article](#) titled "Why the Nation Needs a Diverse Blood Supply." The article is included as an [insert](#) in the publication. The campaign highlights those living with blood disorders and features Tionne "T-Boz" Watkins, a member of the four-time Grammy Award winning group TLC, who lives with sickle cell disease. The estimated circulation of the insert is 200,000 copies reaching approximately 600,000 readers.

Participate in the ABC Employee and Retention Survey

ABC has launched our Employee Turnover and Retention Survey for calendar year 2020. We would like to achieve a 100 percent response rate. Questions focused on COVID-19 experiences and policies have been added to the survey. Your participation in completing this survey helps ensure the results will be a valuable tool for the entire ABC membership, particularly in addressing the human resources sections of your emergency and disaster preparedness plans. Survey results will be reported in the aggregate and made available on the ABC Member Portal.

Please contact [us](#) for a copy of the MCN which includes a link to the survey.

(Source: MCN 21-033, 4/12/21)

ABC Seeks Member Participation in 2020 Service Fee Survey

America's Blood Centers has launched the annual survey of member service fees. Members are encouraged to participate by completing the online survey available in MCN 21-032. The results from this survey are important in assisting ABC in its advocacy efforts on behalf of member blood centers for better reimbursement for blood products. Only aggregate data will be reported and no individual data or identifiable information from any center will be shared. Please contact [us](#) to receive a copy of the survey questions or see MCN 21-032.

(Source: MCN 21-032, 4/8/21)

ADRP Master Class Designed for Your Collections and Recruitment Teams

This year's [workshop](#) is focused on elevating the donor journey and catered to the needs of your collections and recruitment teams, the latter of which have a unique role in setting the foundation with donors, communicating key details on what they can expect during the blood donation process. Your collections teams provide the donor the experience which will stay with them forever, dictating if and when they return. Both teams are integral in the donor journey. The Master Class program will also address staff management and how to create a culture to deliver top-notch service. It includes a great mix of presenters, both from blood

(continued on page 6)



INSIDE ABC (continued from page 5)

centers across the globe and from well-known companies such as Chick-fil-A and The Ritz-Carlton. In addition to these speakers, the workshop will have attendees from community blood centers, hospitals, and the American Red Cross, representing U.S., Canada, Scotland, Ireland, and China. [Registration](#) remains open. View the complete [program](#) and register [here](#) today. 💧

PEOPLE

Micheal Deininger, MD, PhD has been [named](#) Executive Vice President, Chief Scientific Officer at Versiti, and Director of the Versiti Blood Research Institute. Dr. Deininger previously served as a Professor at the University of Utah and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the Huntsman Cancer Institute. Other roles at Huntsman included senior director of Transdisciplinary Research and director of the Huntsman Center of Excellence in Hematologic Malignancies and Hematology. “We are excited to have a world-renowned researcher and leader of Mike’s caliber join Versiti as our inaugural Mike and Cathy White Endowed Chair,” said Chris Miskel, MBA, president and Chief Executive Officer of Versiti in a news release. “The Versiti Blood Research Institute is known globally for research related to blood health. Given his proven scientific excellence, translational research focus, leadership experience, and clinical expertise, I am confident that Mike will take the institute to a new level. He is deeply committed to advancing scientific discovery in hematology, the science of blood in health and disease, and to translating the new knowledge into benefit for patients.” Dr. Deininger added, “I am excited to join the team at Versiti and the Versiti Blood Research Institute. Leading this crown jewel of the academic medical research campus in Milwaukee and well beyond is a privilege, challenge, and mandate for excellence. From my own research work, I know that hematology connects to all fields of medicine. I have no doubt that the Institute is poised to reach new heights. We will nurture a culture where everyone in the organization is committed to rigorous scientific pursuit in a collegial environment and celebrates the sheer joy of scientific discovery and the difference we can make to patients’ lives. The sky is the limit.” He succeeds Roy Silverstein, MD, who served as interim head of the Versiti Blood Research Institute. Dr. Deininger begins his new role on September 1st. Prior to his time at the Huntsman Cancer Institute, he held several positions at the Oregon Health and Science University, Portland, Ore., including chief of the Hematological Malignancies section. According to the news release, “Dr. Deininger has extensive experience treating patients with blood cancers, including chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia. He is highly published, twice being named by Thomson Reuters as among the world’s most cited researchers. He holds a degree in medicine from the University of Würzburg, Germany and a PhD from Imperial College, London.”




(Source: Versiti [News Release](#), 4/22/21) 💧





COVID-19 Convalescent Plasma Updates

Convalescent Plasma: Industry Collections and Distributions



GLOBAL NEWS

A [report](#) in *The Guardian* says **Lifeblood (formerly the Australian Red Cross Blood Service) is weighing revising the current variant Creutzfeldt-Jakob disease (vCJD) deferral.** It prevents individual who lived in or visited the United Kingdom (UK) for six months or more during period of 1980-1996 from donating. *The Guardian* states that Lifeblood intends to submit a proposed change to the Australian regulatory authority in the near future. “Our submission is currently being reviewed by external medical experts, prior to consideration by the Australian regulator, the Therapeutic Goods Administration,” said a spokeswoman for Lifeblood to the publication. “We look forward to having more to say about our submission in future. Lifeblood would like to make it easier for all Australians to give blood, while ensuring Australia’s blood and blood products are as safe as possible for blood recipients.” In 2020, the U.S. Food and Drug Administration (FDA) updated its guidance titled [“Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components.”](#) Changes included removal of the deferral criteria for geographical risk of vCJD for U.S. military bases in Europe, which America’s Blood Centers actively advocated in favor of for many years, and excludes time in United Kingdom from 1980-1996 (cumulative 3 months), and France or Ireland from 1980-2001 (cumulative 5 years). vCJD, the human form of Bovine Spongiform Encephalopathy (BSE), is a fatal, progressive neurological condition that was first identified in the U.K. in 1996. It is generally transmitted by eating the beef of animals affected, though a few cases have been found to result from blood transfusion from donors that appeared healthy at the time of donation but later developed vCJD.

(Source: *The Guardian*, [Australian blood bank reconsidering ban on UK donations from ‘mad cow disease’ era](#), 4/19/21)

The European Medicines Agency (EMA) safety committee (PRAC) **“concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen (Johnson & Johnson).** PRAC also concluded that these events should be listed as very rare side effects of the vaccine.” The agency added that “[t]he reported combination of blood clots and

(continued on page 8)

GLOBAL NEWS (continued from page 7)

low blood platelets is very rare, and the overall benefits of COVID-19 Vaccine Janssen in preventing COVID-19 outweigh the risks of side effects.” This clears the way for member European nations regulated by the agency to distribute the vaccine. The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is meeting April 23rd to make a recommendation regarding the COVID-19 Vaccine Janssen after regulators in the U.S. paused distribution of the vaccine, which had previously received emergency use authorization from the U.S. Food and Drug Administration (FDA), prior to reports of blood clots developing in eight individuals potentially linked to the vaccine. More than 7 million doses of the vaccine have been administered in the U.S. A [statement](#) from the FDA and CDC on April 13th said, “[r]ight now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the [Johnson & Johnson] vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.”

(Sources: EMA [News Release](#), 4/20/21; FDA and CDC [Joint Statement](#), 4/13/21) ♦

COMPANY NEWS

Blood Centers of America (BCA) recently [honored](#) 10 of its supply partners with “Critical Infusion Awards.” This distinction recognizes the organizations for their role in assisting the blood and plasma communities in overcoming the unique challenges caused by the pandemic in disrupting operations. The awardees were particularly helpful in “[keeping] the supply chain moving during the pandemic” and “went above and beyond to to solve logistics, testing and equipment supply challenges” in the coordination and collection of COVID-19 convalescent plasma (CCP). “We received so many thank you notes from grateful patients that received CCP and felt that it saved their lives,” said BCA Board Chair John Hagins in a news release. “BCA and its member blood centers recognize that we could not have collected and distributed CCP to patients in need without our supplier partners supporting us behind the scenes.” BCA President and Chief Executive Officer (CEO) Bill Block added in the release, “The pandemic did not stop the demand for blood and plasma donations – in fact, it significantly increased it in some cases. We are so grateful for our partners across the supply chain, who all kept these critical supplies moving despite significant, unprecedented challenges. Congratulations to our Critical Infusion Award recipients. We commend your resiliency and flexibility throughout the COVID-19 pandemic.” Honorees included the following diagnostics, logistics and distribution, and medical plastics companies and manufacturers:

- Abbott;
- Bio Pharma Logistics;
- Fresenius Kabi;
- Henry Schein Medical;
- MNC Global Logistics;
- OptiFreight® Logistics;
- Ortho Clinical Diagnostics;
- Roche Diagnostics;
- Terumo Blood and Cell Technologies; and
- Thermo Fisher Scientific.

(Source: BCA [News Release](#), 4/21/21)

(continued on page 9)

COMPANY NEWS (continued from page 8)

Grifols announced that it is donating 240 million international units (IU) of Factor VIII and Factor IX blood clotting therapies to the World Federation of Hemophilia (WFH) over the next eight years. The donation is an extension of a partnership that began in 2014 and will bring the total number IUs of Factor VIII and Factor IX to 440 million by the year 2030. “Since its creation in 1996, the WFH Humanitarian Aid Program has benefitted almost 100,000 people in over 100 countries,” said Alain Baumann, CEO of WFH in a news release. “When patients are able to receive consistent and reliable access to treatment and care, they have hope for a better quality of life.” The new commitment by Grifols is projected to help an estimated 3,000 patients annually in developing countries. “Helping to address global health inequities is an essential part of fulfilling our corporate mission,” stated Victor Grifols Deu, co-CEO of Grifols in the news release. “We consider product donations to [WFH] to be an ethical imperative for our company rather than a simple choice,” added Raimon Grifols, co-CEO of Grifols.

(Source: Grifols [News Release](#), 4/15/21) 💧

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org or by fax to (202) 899-2621. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

2021

May 4-6. **IPFA/PEI 27th International Workshop on Surveillance and Screening of Blood-borne Pathogens (Virtual)**. More details available [here](#).

May 6. **FDA CBER OTAT Patient Engagement and Regenerative Medicine Workshop (Virtual)**. More details available [here](#).

May 12-13. **Elevate Your Donor Journey: ADRP Master Class in Finding Your XFactor (Virtual)**. More details available [here](#).

May 21-22. **64th Annual California Blood Bank Society Annual Meeting (Virtual)**. More details available [here](#).

Aug. 4. **ABC Medical Directors Workshop, Cleveland, Ohio**. More details coming [soon](#).

(continued on page 10)

CALENDAR (continued from page 9)

Aug. 5-6. **ABC Summer Summit, Cleveland, Ohio.** More details coming [soon](#).

Aug. 17-19. **2021 ADRP Conference, Kansas City, Mo.** [Registration](#) is open. More details available [here](#).

Sept. 15-17. **4th European Conference on Donor Health and Management, Hamburg, Germany.** More details available [here](#).

Oct. 16-19. **AABB Annual Meeting.** More details available [here](#). ♦

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Manager of Donor Recruitment. The Manager of Donor Recruitment will be responsible for overseeing all Donor Recruitment and Telerecruitment staff. They will be expected to take initiative to come up with fresh ideas and be able to successfully implement them utilizing both teams. The Manager of Donor Recruitment will work fluidly with the Mobile Collections department to ensure mobile drive success and maximize blood collection. In addition, they will work routinely with the Director of Communications to plan events and coordinate donor incentives. The Manager of Donor Recruitment will be expected to support the Donor Recruiters in managing their large client accounts, and in some cases may manage special client accounts. Requirements include a bachelor's degree in Business or related field, supervisory experience, and account management experience. Anyone interested can send their resume to Katy Stout at kstout@medicblood.org.

Manager of Mobile Collections. The Manager of Mobile Collections will be responsible for overseeing all of the Mobile Collections staff and operations. Primary functions will include ensuring all equipment is prepared and ready for use, confirm adequate staffing levels for all mobile blood drives, and provide support to the team where needed daily. They will be required to work fluidly with the Manager of Donor Recruitment to ensure mobile blood drive success and maximize blood collection. Requirements include a High School Diploma or equivalent, supervisory experience, clinical experience, and BLS certification. Anyone interested can send their resume to Katy Stout at kstout@medicblood.org.

Blood Donor Collections Manager (Blood Donor Center; Massachusetts General Hospital, Harvard Medical School). The Massachusetts General Hospital Blood Donor Center is currently hiring a Collections Manager. The Donor Collections Manager is responsible for the organization and management of Donor Service In-House collection facilities, the Blood Donor Mobile

Units, and the Component Processing Laboratory, as well as, the implementation of policies and procedures, staffing and evaluation of all staff. The Donor Collections Manager has a primary reporting relationship to the Medical Director and a secondary reporting relationship to the Director of Operations, Lab and Molecular Medicine. The Donor Collections Manager is functionally responsible for coordinating clinical, educational, and administrative activities of the Blood Donor Center, Blood Donor Mobile Units, Apheresis Collections, and the Component Processing Lab. The Donor Collections Manager is an extension of the Medical Director and works to ensure competent, compassionate care to the donors, and to their families. The Standards of Practice of the AABB and the Philosophy of the Blood Donor Center form the basis of such care. The ideal candidate will have three to five years of supervisory experience in blood collection and bachelor's degree. To view the complete job posting and apply, please click [here](#). Interested candidates can also contact Elana Greenfield at egreenfield1@mg.harvard.edu.

Bring your talent and expertise to the beautiful sunny state of Florida in one of these exciting opportunities with OneBlood: **Compatibility Testing Lab Supervisor (Tallahassee, FL - \$7.5k Bonus Eligible)**. Bachelor's degree in medical technology, biological science, or related field and three plus years in a clinical laboratory, preferably in blood banking. Requires a current Florida Technologist license in Immunohematology or Blood Banking; FL Supervisor License preferred. **Medical Technologist (Tallahassee and Ft. Lauderdale, FL - \$5k Bonus Eligible)**. A valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking is required. Prior blood banking experience preferred. Multiple shifts available. **Registered Nurse (Ft. Lauderdale, FL - \$7.5k Bonus Eligible)**. Current and valid Florida RN license, current BLS CPR

(continued on page 11)

POSITIONS (continued from page 10)

certification, and a valid and clear driver's license is required. Flexibility in scheduling needed to meet the needs of the department; travel within the tri-county market in the South Florida area is required. OneBlood offers competitive benefits, including excellent shift differential pay for night and weekend schedules, Paid Time Off, Student Loan Repayment Program, a **FREE** medical coverage option, 403(b) Retirement Plan, company-paid annual CEU training & CE Broker account and MORE! To apply visit our OneBlood careers website at www.oneblood.org/careers.

Innovation and Product Development Manager. Stanford Blood Center (SBC) is seeking an Innovation and Product Development Manager. Under the general direction of the CEO and Medical Directors, the SBC Innovation and Product Development Manager will provide scientific direction to the Innovation team and serve as a core resource to all diagnostic laboratories for diagnostic assay development and improvement, and technology assessment, while providing leadership and management for the Innovation team, to ensure the ongoing vitality, expansion, and innovation of the labs. Will work effectively with all Medical Directors to define research and development priorities, assess the diagnostic operational needs, and new diagnostic opportunities, allocate resources and ensure the successful conclusion of projects. Core duties include Laboratory Operations, Planning, Scientific Leadership, Quality Assurance & Regulatory Compliance, Team Leadership, Financial Management, Customer Service. For a complete job description and to apply, please visit: <https://careers.stanfordhealthcare.org/us/en>, and reference job # R213807. Thank you for your interest! 💧